Quantitative PCR Using a Nanofluidic Platform to Quantify Bcr-Abl mRNA in Patients Who Are Negative by Routine Quantitative PCR Testing.
Authors: Oehler Vivian G. , Helton Bret , Kalebic Thea , Radich Jerald P. 
Published: October 2019

Abstract 3300

Poster Board III-188

Imatinib mesylate (IM) has dramatically changed the management of chronic phase (CP) chronic myeloid leukemia (CML), with more than 80% of treated patients alive and free from transformation after 8 years of therapy. Long-term studies suggest that molecular response appears to increase in some patients over time and a significant minority of patients eventually obtain a “molecular remission”, where quantitative PCR (QPCR) for the bcr-abl transcript is negative. Two IM cessation trials have been conducted in a total of 90 patients who were consistently negative by QPCR. In each trial ∼40-50% of patients had molecular relapse after IM was stopped. Thus, despite the fact that IM, as well as dasatinib and nilotinib, do not appear to target CML stem cells, it appears that some patients may be able to stop IM therapy in the short-term, if not the long-term. These data suggest that different “kinetic” profiles exist: in some patients bcr-abl continues to decline, whereas in others it may plateau or even increase. In order to study this phenomenon, a more sensitive method of molecular detection is required. We utilized a nanofluidic platform (Fluidigm Corporation, South San Francisco, CA) to detect and quantify rare copies of bcr-abl mRNA. In this assay, detection sensitivity is augmented by sample partitioning prior to PCR, such that multiple QPCR reactions are performed simultaneously in hundreds of replicates. Initial bcr-abl copy number is calculated using the Poisson distribution. The assay was first optimized to reproducibly detect a single copy of bcr-abl using plasmids and bcr-abl positive cell lines in a background of bcr-abl negative cell lines. We then examined longitudinal samples (4-5 samples per patient) from 8 CP CML patients enrolled on the Novartis-sponsored TOPS trial who were in a molecular remission by QPCR. Among 33 patient samples, 7 samples were positive by QPCR and 26 samples were negative by QPCR. The Fluidigm nanofluidic QPCR assay was positive in all 7 samples positive by QPCR and was positive in 11 of 26 quantitative negative PCR samples (42%). Eleven of the 33 samples were also negative by a sensitive nested qualitative PCR assay performed in duplicate. Bcr-abl was detected using the nanofluidic QPCR assay in 1 of 11 of these samples (9%). Bcr-abl was not detected in 3 normal peripheral blood samples or in 3 bcr-abl negative cell lines. In one patient nanofluidic QPCR over time identified increasing bcr-abl 6 months before molecular relapse was evident by routine QPCR (Figure 1a,b). In 5 patients bcr-abl decreased or was stable over time (Figure 1b). In two patients persistently negative by both quantitative and nested qualitative PCR no bcr-abl was detected over time.

Conclusion

The nanofluidic QPCR assay can detect bcr-abl in ∼40% of cases negative by routine QPCR and can detect increasing bcr-abl copies many months before it is evident by routine QPCR testing. Interestingly, this detection frequency is similar to the relapse rate in molecular remission patients after IM is discontinued. This observation suggests the assay may be valuable in monitoring for molecular relapse, potentially in ongoing IM cessation trials.

Disclosures

Radich: Novartis: Consultancy, Honoraria, Research Funding.